By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Archemix Corporation 

148 Sidney Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-621-7700 Fax: 617-621-9300



Company News
Geron Corporation (GERN): A Tribute to Alex Barkas 11/23/2011 10:06:47 AM
Baxter International, Inc. (BAX) Announces Acquisition of All Hemophilia-Related Assets of Archemix Corporation and an Exclusive License of Its Anti-TFPI Aptamer Technology for $30 Million Upfront Plus Possible $285 Million More in Milestones 11/19/2010 7:47:11 AM
miRagen Therapeutics and Archemix Corporation to Collaborate on Conjugated Aptamer-microRNA Therapeutics 7/23/2009 9:29:23 AM
Archemix Corporation and Dicerna Pharmaceuticals to Collaborate on Conjugated Aptamer-Dicer Substrate RNAi Therapeutics 7/21/2009 6:53:02 AM
Archemix Corporation Appoints Ken Bate as President and Chief Executive Officer 5/6/2009 7:07:25 AM
Archemix Corporation Initiates Phase 2a for Lead Aptamer Product Candidate ARC1779 3/30/2009 8:47:03 AM
Archemix Corporation Merger with NitroMed, Inc. (NTMD) Falls Through 1/28/2009 8:29:08 AM
Archemix Corporation Announces Continued Progress with Business Strategy 1/27/2009 2:20:04 PM
GlaxoSmithKline (GSK) (JOBS) and Archemix Corporation Form Strategic Alliance Worth $1.4 Billion to Develop Aptamers to Treat Inflammatory Diseases 12/23/2008 6:50:27 AM
Archemix Corporation Announces ARC1779 Data to Be Presented at Upcoming American Society of Hematology Annual Meeting, December 6-9, 2008 12/4/2008 9:17:14 AM